| abstract |
The invention provides a stable pharmaceutical composition containing biologically active human interferon-β (IFN-β), preferably IFN β-1b produced in a bacterial host, dissolved in an aqueous-based solution containing a glycine buffer at a pH of about 2.0 to about 4.0. The invention of also provides stable IFN-β lyophilizates prepared from biologically active IFN-β, dissolved in an aqueous-based solution containing a glycine buffer at a pH of about 2.0 to about 4.0. |